https://www.selleckchem.com/products/danicamtiv-myk-491.html To compare the contributions of cardiac MRI and PET in the diagnosis and management of cardiac sarcoidosis (CS), with particular reference to quantitative measures. This is a retrospective, observational study of 31 patients (mean age, 45.7 years) with proven extracardiac sarcoidosis and possible CS who were investigated with fluorine 18 fluorodeoxyglucose (FDG) PET/CT and cardiac MRI. Patients were treated at physicians' discretion with repeat combined imaging after an interval of 102-770 days (median, 228 days). Significant myocardial FDG uptake was shown on visit 1 (myocardial maximum standardized uptake value [SUV ] > 3.6) in 17 of 22 patients who were subsequently treated. Myocardial SUV decreased at follow-up (6.5 to 4.0; < .01) and was matched by significant decreases in FDG-avid lung and mediastinal node disease. A volumetric measure of myocardium above a threshold SUV (cardiac metabolic volume) decreased from a mean of 42.5 to a mean of 4.1 ( < .001). This was associated with sents who were untreated showed no change in any parameter. Quantification of FDG-avid myocardium using cardiac metabolic volume is proposed as a useful objective measure for assessing response to therapy.© RSNA, 2020See also commentary by Gutberlet in this issue. To evaluate the Radiological Society of North America (RSNA) chest CT classification system for reporting coronavirus disease 2019 (COVID-19) pneumonia. Chest CT scans of consecutive patients suspected of having COVID-19 were retrospectively and independently evaluated by two chest radiologists and a 5th-year radiology resident using the RSNA chest CT classification system for reporting COVID-19 pneumonia. Interobserver agreement was evaluated by calculating weighted κ coefficients. The proportion of patients with real-time reverse-transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19 in each of the four chest CT categories (typical, indeterminate, aty